Patients get extended access to experimental drug in safety Follow-Up
NCT ID NCT07456891
Summary
This study allows participants who benefited from remibrutinib in previous Novartis trials to continue taking the medication for up to three years. It aims to collect long-term safety data on the drug. The study is open to people with skin or allergy conditions who cannot access the drug outside of a clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDICATION OF THE PARENT PROTOCOL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.